Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT

• Conditions: Acute Kidney Failure With or Without: MODS; Sepsis; Hepatic Insufficiency

• Registration Number: NCT00948558
• Lead Sponsor: Huashan Hospital

Brief Summary

1. To compare the differences of citrate pharmacokinetics in healthy individuals and critically ill patients as well as the influential factors.

2. To validate a pharmacokinetic model which has been established in a formal paper.

3. To create a safe and effective RCA-CRRT protocol.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-03
• Study First Submitted: 2009-07-28
• Study First Submitted QC: 2009-07-28
• Study First Posted: 2009-07-29
• Status Verified: 2009-08
• Last Update Submitted: 2009-08-04
• Last Update Posted: 2009-08-06
• Primary Completion: 2010-12
• Study Completion: 2011-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• healthy individuals, none-pregnant
• diagnosed with acute renal failure according to RIFLE criteria
• ARF with hepatic insufficiency
• ARF with MODS or sepsis
• within informed consent

Exclusion Criteria

• used drugs with citrate within one week
• infused with blood,plasma or platelet or undergone plasma exchange therapy within 48 hours
• serious alkalosis with PH>7.55
• serious lactic acidosis
• not in resuscitation state

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Huashan hospital; 🇨🇳 Shanghai, China